

| Line Number | Hits | Search Text | DB | Time stamp |
|-------------|------|---|---|------------------|
| 12 | 104 | (smooth adj muscle adj7 promoter) and enhancer | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 12:55 |
| 13 | 104 | (smooth adj muscle adj7 promoter) and (enhancer or CMV-IE) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 12:56 |
| 14 | 31 | (smooth adj muscle adj7 promoter) same (enhancer or CMV-IE) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 14:38 |
| 15 | 0 | "199824922" | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:07 |
| 16 | 1 | "98/24922" | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:07 |
| 17 | 3887 | coleman.in. | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:08 |
| 18 | 41 | coleman.in. and actin | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:08 |
| 19 | 2 | coleman.in. and actin adj gene | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:08 |
| 20 | 1 | (coleman.in. and actin adj gene) and (enhancer or CMV-IE) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:15 |
| 21 | 2 | (coleman.in. and actin adj gene) and (promoter) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:24 |
| 22 | 10 | "9309236" | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 13:25 |
| 23 | 11 | schwartz.in. and myogenic adj vector | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 14:22 |
| 24 | 4 | "6074850" and enhancer | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB | 2003/07/17 14:22 |

| | | | |
|----|--|---|------------------|
| 25 | 61 ((smooth adj muscle adj7 promoter) same (enhancer or CMV-IE or RSV or SV40 or EF1a)) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:38 |
| 26 | 51 ((smooth adj muscle or SMact or SM22) adj5 promoter) same (enhancer or CMV-IE or RSV or SV40 or EF1a) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:39 |
| 27 | 33 ((smooth adj muscle or SMact or SM22) adj3 promoter) same (enhancer or CMV-IE or RSV or SV40 or EF1a) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:40 |
| 28 | 16 ((smooth adj muscle or SMact or SM22) adj3 promoter) same (enhancer or enhancer adj5 (CMV-IE or RSV or SV40 or EF1a)) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:41 |
| 29 | 25 ((smooth adj muscle or SMact or SM22) adj5 promoter) same (enhancer or enhancer adj5 (CMV-IE or RSV or SV40 or EF1a)) | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:44 |
| 30 | 25 ((smooth adj muscle or SMact or SM22) adj5 promoter) same (enhancer or enhancer adj5 (CMV-IE or RSV or SV40 or EF1a)) and enhancer | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:49 |
| 31 | 25 ((smooth adj muscle or SMact or SM22) adj5 promoter) same (enhancer or enhancer adj5 (CMV-IE or RSV or SV40 or EF1a)) and smooth adj muscle | USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB | 2003/07/17 14:49 |

• THE NEILSON REPORT
• IN U.S. DOLLARS

| SOURCE FILE | TOTAL |
|-------------|---------|
| ENTRY | SESSION |
| 1.21 | 1.21 |

FILE 'MEDLINE' ENTERED AT 16:28:26 ON 17 JUL 2003

FILE 'VAPING' ENTERED AT 16:42:12Z ON 17 JUL 2013
LIVE OR STAGED TO THE TERMS OF YOUR STA/WTIMER AGREEMENT.
PLEASE SEE 'HELI USA PTERMS' FOR DETAILS.
LIVEBIRD 1440 AMERICAN CHEMICAL SOCIETY ACT

IS A PROMOTER A SINGLE OR SMART OR SM22' TFI PROMOTER, S' ENHANCER OR ENHANCER TFI, TFI B OR BTF OR BTF41 OR BTF42
 UNMATCHED PARENTHESES TFI(PROMTER, S')
 The number of right parentheses in a query must be equal to the
 number of left parentheses.

The number of right parentheses in a query must be equal to the number of left parentheses.

→ d. 1110 abs 1.2

LI ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ASSIGNMENT NUMBER: 2002141639 CAPLUS
DOCUMENT NUMBER: 146180961
TITLE: Chimeric promoters for controlling expression in smooth muscle cells
INVENTOR(S): Ribault, Sébastien; Neville, Paschal; Nehme, Majid
PATENT ASSIGNEE(S): Transgene S.A., Fr.
COUNTRY: PCT Int. Appl., 58 pp.
COPEN: P10002
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

10. ANSWER 2 OF 2: TAKING A PILOT FLIGHT 2003 APR
AIRCRAFT NUMBER: 200312240849 TAKING
C. AIRPORT NUMBER: 1451299447
TITLE: Numerical Strength, the
Valuable Tools for Add
itive Element

AUTHOR: : Kirnait, Sébastien; Neville, Pascal;
Mathieu Neville, Ames; Alje, Patrice; Barlaasian,
Ara; Batriani, Brigitte; Bellin, Denise; Calenia,
Valerie

APPROPRIATE SOURCE: Cardiovascular Gene Therapy Laboratory, Strasbourg,
67000, Fr.

TYPE: Circulation Research, 2001, 98 (5), 469-475

EDITION: TIBBAL; ISBN: 0009-1290

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB: Gene transfer with adenoviral vectors is an attractive approach for the treatment of atherosclerosis and restenosis. However, because expression of a therapeutic gene in non-target tissues may have deleterious effects, artery-specific expression is desirable. Although expression vectors using transcriptional regulatory elements of genes expressed solely in smooth muscle cells (SMs) have proved efficient to restrict expression of the transgene, their use in the clinic setting can be limited by their reduced strength. In the present study, we show that low levels of transgene expression are attained with the smooth muscle (SM)-specific SM22.alpha. promoter compared with the viral cytomegalovirus (CMV) enhancer promoter. We have generated chimeric transcriptional cassettes comprising either a SM-SM myosin heavy chain or a skeletal muscle (creatine kinase) enhancer combined with the SM22.alpha. promoter. With both constructs we observed significantly stronger expression that remains SM-specific. In vivo, reporter gene expression was restricted to arterial SMs with no detectable signal at remote sites. Moreover, when interferon- γ expression was driven by one of these two chimeras, SMC growth was inhibited as efficiently as with the CMV promoter. Finally, we demonstrate that neointima formation in the rat carotid balloon injury model was reduced to the same extent by adenoviral gene transfer of interferon- γ , driven either by the SM-myosin heavy chain enhancer SM22.alpha. promoter or the CMV promoter. These results indicate that such vectors can be useful for the treatment of hyperproliferative vascular disorders.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT